Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

WHO Evaluation: Sansure Biotech Kit Shows Excellent Performance in Detecting Monkeypox Virus
2022-10-28

Recently, under the guidance of WHO, The Robert Koch Institute (RKI), a German Reference Laboratory for Poxviruses, conducted overall evaluation on eleven PCR kits for the detection of Monkeypox Virus (MPXV) DNA, among which Sansure shows excellent performance in terms of both detection rate and specificity. Since May 2022, the rapid communication of Monkeypox around the world, especially in Europe […]

LEARN MORE
The TSure Nucleic Acid Analysis Device from Sansure Obtained CE Mark
2022-09-23

Recently, the TSure Nucleic Acid Analysis Device independently developed by Sansure obtained CE mark, which will further meet and expand the global testing market demands at all levels, and serve the construction of public health prevention and control system in every country better. Sansure’s TSure Nucleic Acid Analysis Device is a portable device that can carry LAMP thermostatic amplification reagent […]

LEARN MORE
Sansure’s HIV-1 RNA Diagnostic Kit is Approved for Marketing
2022-09-15

Recently, the Human Immunodeficiency Virus Type 1 RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing) independently developed by Sansure Biotech has been reviewed and approved for marketing by the National Medical Products Administration (NMPA Registration No.: 20223401175). The reagent is applicable to the quantitative detection of Human Immunodeficiency Virus Type 1 RNA in human blood samples and monitor the virological response […]

LEARN MORE
Sansure and QuantuMDx, to jointly build intelligent and diversified overall solution for POCT
2022-09-08

Recently, Sansure Biotech reached a strategic cooperation agreement with QuantuMDx Group Co., LTD. (hereinafter referred to as QuantuMDx) to establish cooperation relationship for global R&D and production. The two companies will further cooperate on the Q-POC™ platform, to develop multiple tests, expand the menu, and bring a series of innovative and high-performance tests. QuantuMDx is a fast-growing medical technology company […]

LEARN MORE
HPV DNA (23 genotypes) Diagnostic Kit from Sansure Biotech is Approved by NMPA
2022-08-10

Recently, Human Papillomavirus DNA (23 genotypes) Diagnostic Kit (PCR-Fluorescence Probing) independently developed by Sansure Biotech was approved for marketing by NMPA (National Medical Products Administration). This marks a milestone for Sansure Biotech: the enterprise with the most certified products and the most complete solutions in the field of HPV DNA testing in China, adding a new competitive product to HPV diagnostic […]

LEARN MORE
×
Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.
SUBMIT

Thank you!

We shall contact you soon!
Back Top